Company Profile (AI Text)
Name: TTC Oncology
Canonical URL: https://wefunder.com/ttc.oncology
Updated at: 2026-06-02T05:00:40Z

Tagline: Treating breast cancer with safe, simple & effective therapy.
Elevator pitch: We have developed new treatment for breast cancer.

Key claims:
- Total raised on Wefunder: 141830 | citation: https://wefunder.com/ttc.oncology#claim-total-raised
- Total investors: 69 | citation: https://wefunder.com/ttc.oncology#claim-total-investors

Verified facts:
- Total raised on Wefunder: 141830 | observed_at: 2026-06-02T05:00:40Z | expires_at: 2026-06-03T05:00:40Z
- Total investors: 69 | observed_at: 2026-06-02T05:00:40Z | expires_at: 2026-06-03T05:00:40Z

Computed metrics:
- total_amount_raised: 141830
- total_investors: 69
- team_size: 7
- featured_investor_count: 1
- faq_count: 5
- recent_post_count: 3

Quick facts:
- Ending Toxic Treatments For Breast Cancer Patients with Therapeutic Oral Capsule TTC-352 | citation: https://wefunder.com/ttc.oncology#claim-fact-1
- Successfully completed US FDA Phase 1 study with clear path through Approval to market | citation: https://wefunder.com/ttc.oncology#claim-fact-2
- Team has combined 45 Years Oncology Research + 30 Years Drug Development Experience | citation: https://wefunder.com/ttc.oncology#claim-fact-3
- Successfully raised $1.35M in initial seed round plus $6.25M through 1st trial | citation: https://wefunder.com/ttc.oncology#claim-fact-4
- $55.27B Global market projected by 2027, CAGR 13.1% | citation: https://wefunder.com/ttc.oncology#claim-fact-5
- Team has prior profitable investor Exit through acquisition, based on new drug development | citation: https://wefunder.com/ttc.oncology#claim-fact-6
- Worldwide exclusive rights through University of Illinois, 2 US Patents — international pending | citation: https://wefunder.com/ttc.oncology#claim-fact-7
- Intellectual property protected up to 2033 | citation: https://wefunder.com/ttc.oncology#claim-fact-8

FAQ:
- Q: What is your Valuation Cap for this offering?
  A: Hi Adriane, Thank you for your interest in TTC Oncology. Our valuation cap is $25 million with a 10% discount. Please note that we have a scientific valuation by an independent advisor supporting double that amount. We are doing this valuation cap at $25 million because it's following an earlier raise at a $10 million valuation, and this is "bridge financing" to enable us to order agent ahead of beginning our Phase 2 clinical trials.
- Q: are there going to be more details in the Investment Terms section of this offering? When will your Form- C be available? Thank you!
  A: Hi Adriane, form C was obtained.
- Q: Any plans of furnishing Form-C and other details?
  A: Form C was accepted.
- Q: Hello Dr. Dudek, What cancer cell lines has the TTC- 352 been successful in-vitro, in-vivo, ex-vivo, etc? Any success in combating C-5? Best regards, Miguel Costa
  A: Mr Costa, We tested TTC-352 against the following cell lines: Wild-type (WT) estrogen-dependent breast cancerMCF-7:WS8; mutant p53 estrogen-dependent breast cancer T47D:A18; estrogen responsive, ER-positive, progesterone receptor (PgR)–positive, and HER2-positive luminal B breast cancer BT-474; estrogen responsive, ER-positive, PgR-positive, and androgen receptor–positive luminal A breast cancer ZR-75–1; the first in vitro cellular model recapitulating acquired TAM resistance developed in ath...
- Q: Why have you pursued crowdfunding rather than other avenues?
  A: I am actively pursuing other avenues. I have meetings with VC, family offices and pharma. I am attending JP Morgan and Resi conferences. The reason for crowdfunding is to generate additional data to convince series A investors.

Recent posts:
- Biotech Showcase Follow Up (2022-01-25T17:50:11Z) https://wefunder.com/feed/152250
- News Release (2022-01-14T23:46:09Z) https://wefunder.com/feed/152045
- TTC Oncology has participated in Biotech Showcase 2022 (https://informaconnect.com/biotech-showcase/) where Dr Dudek met with several companies. Further discussion regarding investment, licensing, or partnership are planed after conference. (2022-01-14T23:32:11Z) https://wefunder.com/feed/152044